Proton-pump inhibitor vs. H2-receptor blocker use and overall risk of CKD progression

The relationship between proton-pump inhibitor (PPI) use and chronic kidney disease (CKD) progression remains controversial. Specifically, there is a lack of data evaluating renal outcomes in established CKD patients. The aim of our study is to determine the risk of progression to end-stage kidney d...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BMC nephrology 2021-07, Vol.22 (1), p.264-264, Article 264
Hauptverfasser:	Cholin, Liza, Ashour, Tarek, Mehdi, Ali, Taliercio, Jonathan J, Daou, Remy, Arrigain, Susana, Schold, Jesse D, Thomas, George, Nally, Joseph, Nakhoul, Nazih L, Nakhoul, Georges N
Format:	Artikel
Sprache:	eng
Schlagworte:	Cardiovascular disease Chronic kidney disease Chronic kidney failure Comorbidity Comparative analysis Continuity of care Creatinine Datasets Death Development and progression Diabetes Disease Progression Drug therapy Electronic health records End-stage renal disease Female Hemoglobin Histamine H2 Antagonists - administration & dosage Histamine H2 Antagonists - adverse effects Histamine H2 receptors Histamine-2 receptor blockers Humans Hypertension Incidence Kaplan-Meier Estimate Kidney diseases Kidney Failure, Chronic - diagnosis Kidney Failure, Chronic - mortality Laboratories Male Middle Aged Mortality Negative Results Nephrology Outcome Assessment, Health Care Patients Potassium Prescriptions Proportional Hazards Models Proton pump inhibitors Proton Pump Inhibitors - administration & dosage Proton Pump Inhibitors - adverse effects Registries - statistics & numerical data Regression analysis Renal Insufficiency, Chronic - epidemiology Renal Insufficiency, Chronic - physiopathology Risk Assessment Risk factors Stomach Diseases - drug therapy Stomach Diseases - epidemiology United States - epidemiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The relationship between proton-pump inhibitor (PPI) use and chronic kidney disease (CKD) progression remains controversial. Specifically, there is a lack of data evaluating renal outcomes in established CKD patients. The aim of our study is to determine the risk of progression to end-stage kidney disease (ESKD) or death amongst CKD patients on PPI, histamine-2 receptor blocker (H2B), or no anti-acid therapy. Using our CKD registry, we evaluated the relationship between PPI and H2B use and outcomes amongst patients with CKD (eGFR
ISSN:	1471-2369 1471-2369
DOI:	10.1186/s12882-021-02449-0